When evaluating a new process for viral vector manufacturing, you may be wondering what the best path forward is to save time and resources while ensuring to produce enough data to support the robustness of your future manufacturing and scale-up. Polyplus® free of charge DoE service is the combination of our expertise in the field of nucleic acid delivery and in DoE methodology to support you through the evaluation of our transfection reagents. As each process is different, this service…
Fresh from emerging from stealth, VintaBio says the biggest trend in the CDMO space is excess capacity. VintaBio is a recently launched cell and gene therapy (CGT) contract development manufacturing organization (CDMO), which received $64 million in funding in April to support the opening of its CGT facility in Philadelphia, US. 2023 has seen multiple CDMO’s enter the Life Science space. Last month, the Public Investment Fund (PIF) has launched Lifera, a commercial-scale CDMO to grow Saudi Arabia’s local biopharmaceutical…
Sartorius has opened a 21,500 square-foot cell culture media manufacturing plant at its existing Yauco, Puerto Rico site. The expansion of Sartorius’ cell culture media capacity in Puerto Rico, which opened this week, helps the firm focus specifically on customers in the Americas region. According to the firm, operations began in spring 2023 and will be ramped up throughout the year. Cell culture media are used to feed cells in the manufacture of  therapeutic proteins and various other modalities.…
Novartis adds siRNA therapeutics platform and a preclinical therapy for Charcot-Marie-Tooth disease type 1A (CMT1A) through the acquisition of DTx Pharma. The acquisition sees Novartis pay San Diego-based biotech firm DTx $500 million upfront with the potential of giving a further $500 million dependent on specific milestones. DTx focuses on tackling the delivery challenges of oligonucleotide therapeutics with its Fatty Acid Ligand Conjugated OligoNucleotide (FALCON) platform, which supports production of small interfering RNAÂ (siRNA) therapeutics. In addition to gaining the full…
The Biopharma Development Center will complement a recently announced $400 million biomanufacturing plant says Novartis, ahead of its plans to spin-out Sandoz. In March, Swiss pharma giant Novartis laid plans for a $400 million facility in Lendava, Slovenia to support its Sandoz division’s biosimilar growth ambition. Now the firm will add a dedicated development center nearby in Ljubljana at a cost of $90 million to further support Sandoz’ biosimilars pipeline. Building on its Slovenian infrastructure, along with a biosimilar development…